Recent trends in long-term survival of patients with chronic myelocytic leukemia: Disclosing the impact of advances in therapy on the population level

Haematologica

Volumn 93, Issue 10, 2008, Pages 1544-1549

  Brenner, Hermann ^a   Gondos, Adam ^a   Pulte, Dianne ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Cancer registries; Chronic myelocytic leukemia; Survival; Therapy

Indexed keywords

ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; SURVIVAL TIME; UNITED STATES;

ADOLESCENT; ADULT; AGED; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; SURVIVAL RATE; TIME FACTORS;

EID: 54349101484     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13045     Document Type: Article

References (25)

1. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahmann A, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002;8:935-42.
2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Eng J Med 2001;344:1031-7.
3. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346:645-52.
4. Hehlmann R, Hochhaus A, Baccarani M on behalf of the European LeukemiaNet. Chronic myeloid leukemia. Lancet 2007;370:342-50
5. Xie Y, Davies SM, Xiang Y, Robison LL, Ross JA. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer 2003; 97:2229-35.
6. Brenner H, Gefeller O, Hakulinen T. Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer 2004;40:326-35.
7. Brenner H, Hakulinen T. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol 2006; 164:689-96.
8. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Limited-Use Data (1973-2004), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
9. Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer 1996; 78:2004-10.
10. Brenner H, Soderman B, Hakulinen T. Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in Finland. Int J Epidemiol 2002;31:456-62.
11. Brenner H, Hakulinen T. Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol 2002;20:826-32.
12. Talbäck M, Stenbeck M, Rosen M. Up-to-date long-term survival of cancer patients: an evaluation of period analysis on Swedish Cancer Registry data. Eur J Cancer 2004;40:1361-72.
13. Ellison LF. An empirical evaluation of period survival analysis using data from the Canadian Cancer Registry. Ann Epidemiol 2006;16:191-6.
14. Brenner H, Hakulinen T. Advanced detection of time trends in long term cancer patient survival: experience from 50 years of cancer registration in Finland. Am J Epidemiol 2002;156:566-77.
15. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al. Recent cancer survival in Europe: a period analysis 2000-2002 of the EUROCARE 4 data. Lancet Oncology 2007;8:784-96.
16. Engholm G, Kejs AM, Brewster DH, Gaard M, Holmberg L, Hartley R, et al. Colorectal cancer survival in the Nordic countries and the United Kingdom: excess mortality risk analysis of 5 year relative period survival in the period 1999 to 2000. Int J Cancer 2007;121:1115-22.
17. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 1961;6:101-21.
18. Henson DE, Ries LA. The relative survival rate. Cancer 1995;76:1687-8.
19. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note No. 10. Bethesda, MD. National Cancer Institute; 1959.
20. Arias E. United States life tables, 2000. Natl Vit Stat Rep 2002;51:1-39.
21. Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007;109:4686-92.
22. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "goodrisk" chronic granulocytic leukemia. Blood 1984;63:789-99.
23. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon α. J Natl Cancer Inst 1998;90:850-8.
24. Rosti G, Iacobucci I, Bassi S, Castagnetti F, Amabile M, Cilloni D, et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica 2007;92:101-5.
25. Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003;98:1105-13.